Evaluation of the Comparative Effectiveness of Labetolol andMethyldopa in the Treatment of Pregnancy Induced Hypertension
Abstract
Objective: To compare effectiveness of labetolol and methyldopa in the treatment of pregnancy induced hypertension.Methods
This randomized controlled trial was carried out in the Obstetrics & Gynaecology Department at a Tertiary Care Hospital in Rahim Yar Khan from September 2022 to March 2023. The study involved a total of 84 patients, with 42 patients in each group (Labetalol and Methyldopa). Inclusion criteria encompassed patients aged 20 to 40 years, with gestational age ≥ 20 weeks, and diagnosed with Pregnancy induced hypertension (PIH). The study aimed to compare the effectiveness of Labetalol and Methyldopa in treating PIH.Results
The mean age for the Labetalol group is 29.48 with a standard deviation (SD) of 6.500, while the Methyldopa group has a mean age of 31.55 with an SD of 5.844. The mean gestational age for the Labetalol group is 28.38 weeks with an SD of 4.732, and for the Methyldopa group, it is 29.64 weeks with an SD of 4.509. In the Labetalol group, 38 out of 42 patients (90.5%) experienced efficacy, compared to 30 out of 42 (71.4%) in the Methyldopa group. The P-value of 0.049 suggests that the difference in efficacy between the both study groups is statistically significant, favouring Labetalol as the more effective treatment for pregnancy-induced hypertension.Conclusion
Our study strongly suggests that Labetalol is more effective than Methyldopa in treating pregnancy-induced hypertension, particularly in older age groups. Future research is needed to explore side-effect profiles for a comprehensive understanding.Keywords:
PIH, efficacy, labetalol, methyldopa.Published
2025/03/10
Issue
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments psimjournal@gmail.com